Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 11/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.42 |
| ▸ | CDK2 | P24941 | 11/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 11/20 | 0.42 |
| ▸ | EGFR | P00533 | 5/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10234321 | 0.89 | CHEK1 (0.44) | CHEK1CCNA2CDK2CCNA1FGFR2 | |
| SCHEMBL7875108 | 0.88 | CHEK1 (0.42) | CHEK1CCNA2CDK2CCNA1PIK3CA | |
| SCHEMBL7879860 | 0.88 | CHEK1 (0.42) | CHEK1CCNA2CDK2CCNA1EGFR | |
| SCHEMBL7880787 | 0.88 | CHEK1 (0.42) | CHEK1CCNA2CDK2CCNA1EGFR | |
| SCHEMBL7879875 | 0.88 | CHEK1 (0.41) | CHEK1CCNA2CDK2CCNA1EGFR | |
| SCHEMBL7885772 | 0.85 | FGFR2 (0.36) | CHEK1CCNA2CDK2CCNA1EGFR | |
| SCHEMBL7874486 | 0.84 | MET (0.45) | CHEK1CCNA2CDK2CCNA1EGFR | |
| SCHEMBL7879349 | 0.81 | FGFR2 (0.44) | CHEK1CCNA2CDK2CCNA1EGFR | |
| SCHEMBL6893068 | 0.80 | CHEK1 (0.43) | CHEK1CCNA2CDK2CCNA1EGFR | |
| SCHEMBL6893491 | 0.78 | EGFR (0.39) | CHEK1CCNA2CDK2CCNA1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | CHEK1 461/4885CCNA2 2476/4885CDK2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.